Physician profile
Tracy P Murray
NPI 1942494307
$1,822.26
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $662 · 2023: $777 · 2024: $23.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $294.56 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $275.10 | 2021-2023 | Mounjaro |
| Pfizer INC. | $147.86 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.44 | 2021-2023 | Tradjenta, Synjardy |
| Shield Therapeutics INC | $123.87 | 2022-2023 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $100.84 | 2021-2023 | Farxiga |
| Dexcom, INC. | $66.70 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $56.44 | 2023 | Gemtesa |
| Nevro Corp. | $46.68 | 2023 | Senza |
| Daiichi Sankyo INC. | $46.67 | 2021 | |
| Exact Sciences Corporation | $44.72 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $42.32 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.84 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.78 | 2023 | Xifaxan, Trulance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $35.63 | 2022 | |
| Edwards Lifesciences Corporation | $24.13 | 2021 | |
| Radius Health, INC. | $22.96 | 2022 | |
| Vivus LLC | $21.05 | 2023 | Qsymia |
| Janssen Pharmaceuticals, INC | $19.34 | 2022 | |
| Astellas Pharma US INC | $17.58 | 2023 | Veozah |
| Horizon Therapeutics Plc | $17.13 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $16.49 | 2021 | |
| Allergan, INC. | $16.36 | 2021 | |
| Medtronic, INC. | $15.10 | 2021 | |
| Phadia US INC. | $14.52 | 2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.